Cancer Family
Eye Neoplasm
CI-CAN-00000017Explore in graph →
Non-malignant86 active trials2 approved drugs19 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000017Explore in graph →
Clinical trials
463 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07338968 | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma(CoMpass) | enrolling by invitation | — | 100 | Aura BiosciencesINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 |
| Aug 14, 2026 |
| clinicaltrials |
| NCT06227962 | Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors(RbNeuroQoL) | enrolling by invitation | — | 240 | Amsterdam University Medical CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials